category,datetime,headline,id,image,related,source,summary,url
company,1769526009,Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for,138272542,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,AMGN,Yahoo,Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=8e5848b3a53404331dbfd36a77af07cdf6232f9e96bbb909c25b54c7ca09380c
company,1769505000,Roche Obesity Shot Helps Patients Lose Weight in Midstage Trial,138269287,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,AMGN,Yahoo,"Roche  Holding said an experimental injection achieved positive results in a midstage clinical trial by helping patients shed weight, paving the way for the start of the company’s first late-stage obesity study.  Eli Lilly  and  Novo Nordisk’s  GLP-1 drugs currently dominate the obesity-drug market, but big drugmakers including Roche, Pfizer and Amgen, as well as smaller players, are trying to come up with new treatments to challenge them.  Roche is looking to establish an obesity franchise with several drug candidates under development that it aims to launch as standalone treatments or combined among them, with the goal of becoming a top three player in the market.",https://finnhub.io/api/news?id=8c298ef3b97a7e6659da510c7e0d97e5f8f37afa1b5eb7b32baef59a7516497e
company,1769496756,Bernstein Calls 2026 a “Waiting Year” for Amgen’s (AMGN) MariTide,138268118,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,AMGN,Yahoo,"Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform, while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that “2026 is a waiting year” for […]",https://finnhub.io/api/news?id=f4d7b0a26cfd02dd2f9531e4c5192ee16ea59cd17e447e8dcf071d43559b325f
company,1769490639,"IBB: Beyond The 2025 Surge, Biotech Breakout",138268876,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233342016/image_2233342016.jpg?io=getty-c-w1536,AMGN,SeekingAlpha,"iShares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.",https://finnhub.io/api/news?id=8d2093e4fbe4954a0995724673d028877e1a938b45a84289884c25a074dc7e55
